We are live on
!
Find out more
DCM
Diag Capital Management Portfolio holdings
AUM
$87.4M
This Fund
S&P 500
This Quarter
Est. Return
-15.23%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$87.4M
AUM Growth
–
Cap. Flow
+$93.9M
Cap. Flow
% of AUM
107.42%
Top 10 Holdings %
Top 10 Hldgs %
50.17%
Holding
40
New
40
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$5.77M |
| 2 |
Zimmer Biomet
ZBH
|
+$5.52M |
| 3 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$5.46M |
| 4 |
Incyte
INCY
|
+$4.69M |
| 5 |
CELG
Celgene Corp
CELG
|
+$4.66M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.41% |
| 2 | Miscellaneous | 4.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Baxter International
BAX
$13.5B
| $5.66M | 6.47% |
+85,933
| New | +$5.77M |
|
|
ATNX
2
DELISTED
Athenex, Inc. Common Stock
ATNX
| $5.45M | 6.23% |
+21,452
| New | +$5.46M |
|
|
3
Zimmer Biomet
ZBH
$19.2B
| $4.95M | 5.66% |
+49,115
| New | +$5.52M |
|
4
AbbVie
ABBV
$451B
| $4.65M | 5.32% |
+50,420
| New | +$4.43M |
|
|
5
Incyte
INCY
$25.2B
| $4.59M | 5.25% |
+72,196
| New | +$4.69M |
|
6
Quanterix
QTRX
$125M
| $4.1M | 4.69% |
+223,949
| New | +$4.02M |
|
|
CELG
7
DELISTED
Celgene Corp
CELG
| $4.05M | 4.63% |
+63,159
| New | +$4.66M |
|
8
Amgen
AMGN
$234B
| $3.92M | 4.48% |
+20,110
| New | +$3.92M |
|
9
Medtronic
MDT
$117B
| $3.29M | 3.76% |
+36,180
| New | +$3.38M |
|
|
QTNT
10
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $3.23M | 3.69% |
+13,173
| New | +$3.45M |
|
11
Takeda Pharmaceutical
TAK
$57.6B
| $2.98M | 3.41% |
+177,260
| New | +$2.99M |
|
12
Abbott
ABT
$195B
| $2.79M | 3.19% |
+38,585
| New | +$2.71M |
|
13
Zai Lab
ZLAB
$2.93B
| $2.79M | 3.19% |
+120,092
| New | +$2.23M |
|
14
Viatris
VTRS
$18.8B
| $2.72M | 3.12% |
+99,410
| New | +$3.22M |
|
|
PTE
15
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $2.47M | 2.82% |
+7,313
| New | +$2.65M |
|
|
VRAY
16
DELISTED
ViewRay, Inc.
VRAY
| $2.41M | 2.76% |
+397,375
| New | +$2.98M |
|
17
Regeneron Pharmaceuticals
REGN
$81.8B
| $2.16M | 2.47% |
+5,792
| New | +$2.12M |
|
18
Teva Pharmaceuticals
TEVA
$42.5B
| $2.15M | 2.46% |
+139,531
| New | +$2.86M |
|
|
AKRX
19
DELISTED
Akorn Inc
AKRX
| $2.15M | 2.46% |
+634,046
| New | +$3.77M |
|
20
Haemonetics
HAE
$4.73B
| $2.12M | 2.43% |
+21,220
| New | +$2.23M |
|
21
argenx
ARGX
$64B
| $1.61M | 1.84% |
+16,712
| New | +$1.48M |
|
|
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $1.42M | 1.62% |
+38,319
| New | +$1.38M |
|
23
Merit Medical Systems
MMSI
$5.4B
| $1.4M | 1.6% |
+25,092
| New | +$1.49M |
|
24
Sanofi
SNY
$107B
| $1.31M | 1.5% |
+30,240
| New | +$1.33M |
|
|
GWPH
25
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $1.31M | 1.5% |
+13,460
| New | +$1.77M |
|
Similar funds
JCP
BCEM
QAM
7A
OIMU
SSP
BCA
RCM
Diag Capital Management's Q4 2018 Portfolio in Review
Q4 2018 is the first quarter with a 13F filing on record for Diag Capital Management, which disclosed 40 positions worth $87.4M. Its ten largest holdings account for 50% of the portfolio.
Its largest position is Baxter International: 85,933 shares worth $5.66M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Miscellaneous.
- Diag Capital Management's largest Q4 2018 buy was Baxter International: 85,933 shares worth $5.66M.
- Diag Capital Management's ten largest holdings make up 50% of its $87.4M portfolio in Q4 2018.
- Diag Capital Management disclosed 40 positions in Q4 2018, its first 13F filing on record.
Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.